Adverum Biotechnologies, Inc. Common Stock (ADVM)
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company focused on developing treatments for serious ophthalmic diseases. The company's approach involves using gene therapy to address unmet medical needs, aiming to provide long-term solutions for conditions such as wet age-related macular degeneration and diabetic macular edema. Founded in 2014, Adverum emphasizes innovation in its pursuit to restore or preserve vision through its proprietary delivery platforms.
Company News
The global ophthalmology drugs market is expected to grow from $19.52 billion in 2025 to $26.28 billion by 2030, driven by aging populations, technological innovations, and increasing prevalence of vision-threatening diseases.
ADMA Biologics, Inc. is expected to report strong sales performance for its marketed products in Q2 2024. The company's supplemental BLA approvals for Asceniv and Bivigam are also likely to have boosted sales. Investors will focus on the company's revenue guidance update and pipeline progress.
Braden Michael Leonard, a significant shareholder of Adverum Biotechnologies, has recently purchased over $1.7 million worth of the company's shares, reflecting his confidence in the firm's prospects.
Bloom Energy shares jumped 12.1% after announcing a strategic partnership with CoreWeave to deploy its fuel cells for on-site power generation at a data center. Several other stocks also saw significant pre-market movements, both positive and negative.